ATHENS, Greece, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company providing worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, announced today that its board of directors (the “Board”) has determined to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s issued common shares par value $0.001 (the “Common Shares”), effective at the opening of trading on ...

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-4 reverse stock split effective January 6, 2026, which will reduce the number of outstanding shares while proportionally adjusting the share price [1]. Group 1: Reverse Stock Split Details - The reverse stock split will consolidate every 4 shares of issued and outstanding common stock into one share, resulting in approximately 503,713 shares outstanding post-split, down from approximately 2,014,852 shares [3]. - The trading symbol for the common stock will remain "ELAB," but a new CUSIP number 73017P409 will be assigned [5]. - Outstanding stock awards, options, and shares reserved for the equity incentive plan will be adjusted proportionally to reflect the reverse stock split [5]. Group 2: Impact on Shareholders - Shareholders entitled to fractional shares will receive one full share for each fractional portion [5]. - The reverse stock split does not affect the overall value of shareholder equity; it only reduces the number of shares outstanding while adjusting the share price accordingly [5].

As filed with the Securities and Exchange Commission on December 30, 2025 Registration No. 333-291852 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Edison Oncology Holding Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Nevada 2836 83-1614120 (I.R.S. Employer Identification Number) 3475 Edison Way, ...

HONG KONG, Dec. 26, 2025 /PRNewswire/ -- Intelligent Living Application Group Inc. (Nasdaq: ILAG) (the "Company" or "Intelligent Living"), a premium lockset manufacturer and distributor headquartered in Hong Kong, today announced, on December 15, 2025, the Company held an extraordinary general meeting of the Company (the "Meeting"). At the Meeting, the shareholders of the Company approved to effect a share consolidation/reverse stock split of all the issued and outstanding and authorized and unissued ordin ...

Core Viewpoint - Aptevo Therapeutics Inc. will conduct a reverse stock split at a ratio of 1-for-18, effective December 29, 2025, at 5:01 p.m. [1] Company Summary - Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics [1] - The company utilizes its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies for its therapeutic developments [1]

Core Viewpoint - WORK Medical Technology Group LTD will implement a reverse stock split of its ordinary shares on a 1-for-100 basis to comply with Nasdaq Marketplace Rule 5550(a)(2) regarding minimum bid price requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on December 29, 2025, with Class A ordinary shares trading under the symbol "WOK" and a new CUSIP number G9767H125 [1]. - The reverse stock split has been approved by both the Company's shareholders and board of directors [2]. - Every 100 shares of Class A and Class B ordinary shares will be combined into one share, and fractional shares will be rounded up to the next whole number [3][4]. Group 2: Company Overview - WORK Medical Technology Group LTD, through its subsidiary, is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices [5]. - The company has a diverse product portfolio of 21 products, including customized masks and medical consumables, sold in 34 provincial-level regions in China and over 30 countries worldwide [5]. - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration for entry into the U.S. market [5].

CORSICANA, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that its Board of Directors has approved a 1-for-5 reverse stock split of its common stock (the “Reverse Split”). The Reverse Split will be effective on December 26, 2025, with the Company’s common stock expected to begin trading on a split-adjusted basis at market open on Dec ...

CORSICANA, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that its Board of Directors has approved a 1-for-5 reverse stock split of its common stock (the “Reverse Split”). The Reverse Split will be effective on December 26, 2025, with the Company’s common stock expected to begin trading on a split-adjusted basis at market open on Dec ...

Core Viewpoint - Can-Fite BioPharma Ltd. has announced a 1-for-3,000 reverse split of its ordinary shares, which will take effect on January 2, 2026, with the first trading of the consolidated shares on January 5, 2026 [1][4]. Share Structure Changes - Each outstanding 3,000 pre-split ordinary shares will combine into one new ordinary share automatically, with no action required from shareholders [2]. - The ratio of ordinary shares underlying the Company's American Depositary Shares (ADSs) will change from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, effective January 5, 2026 [2][3]. - The total number of outstanding ordinary shares will decrease from 42 billion to 14 million as a result of the reverse split [4]. Impact on ADS Holders - For ADS holders, the ratio change equates to a one-for-twenty ADS split, requiring the exchange of every 20 ADSs for one new ADS [3]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [6]. Ownership and Voting Power - The reverse split and ADS ratio change will not affect shareholders' percentage ownership or voting power, aside from minimal effects from fractional shares [5]. Market Expectations - The ADS price is expected to increase proportionally due to the change in the ADS ratio, although there is no assurance that the price will be equal to or greater than twenty times the pre-split price [7]. Company Overview - Can-Fite BioPharma Ltd. is focused on developing small-molecule drugs for oncological and inflammatory diseases, with its lead drug candidate, Piclidenoson, in Phase III trials for psoriasis [8]. - The company is also advancing Namodenoson, which is in various stages of trials for liver cancer and has received Orphan Drug Designation in the U.S. and Europe [8].

DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company’s 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company’s common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Market (Nasdaq) ...